Individual decision · SEC · 16 Nov 2009

SEC Division of Corporation Finance no-action letter: Bristol-Myers Squibb Company

securities
market-abuse

The SEC Staff confirms it will not recommend enforcement action against Bristol-Myers Squibb Company for using a pricing mechanism that sets the final exchange ratio two trading days before offer expiration, rather than the standard ten business days required by Rules 13e-4 and 14e-1. This relief allows BMS to determine the ratio based on a three-day volume-weighted average price period ending on the second trading day preceding expiration, providing shareholders two full trading days to consider the final terms. The mechanism includes a maximum exchange ratio limit and pro rata acceptance procedures for oversubscribed tenders.

US FederalSecurities and Exchange Commission

Lineage

The documents this one cites, and the documents that cite it.

Securities Exchange Act of 19341934 · US-LAWSecurities Exchange Act of 1934 (1934-06-06)SEC Division of CorporationFinance no-action letter: Bri…2009-11-16 · this documentSEC Division of Corporation Finance no-action letter: Bristol-Myers Squibb Company (2009-11-16)
amendssupersedesissued underrefers todashed card: not in RegAlert (or proposed)arrows run from the older text to the one that changes it
The links and the sentences they come from (1)
Issued under
  • “Rules 13e-4(d)(I), 13e-4(e)(3), 13e-4(f)(I)(ii) and 14e-l(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")”

More like this from SEC

SEC published 7 documents in the last 30 days. We email you each new one the day it's published.

Source: Securities and Exchange Commission — original document · Summary generated with machine assistance and reviewed before publication; the authoritative text is the regulator's original document. How RegAlert works

In RegAlert: added · updated